Cassava Sciences Announces Positive Topline Results from Cognition Maintenance Study for Alzheimer’s Treatment

Cassava Sciences (Nasdaq: SAVA) has released positive topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study evaluating the efficacy of simufilam in patients with mild-to-moderate Alzheimer’s disease.

The study showed simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in patients with mild-to-moderate disease. Patients with mild disease receiving simufilam demonstrated improved cognition scores over 6 months and stabilized cognition scores over 18 months.

Highlights

The drug favored patients with mild Alzheimer’s disease. Treatment with simufilam for 6 months slowed cognitive decline > 200% compared to placebo.

Cassava’s study enrolled 157 patients with mild-to-moderate Alzheimer’s disease, a more advanced and difficult-to-treat stage of disease.

In the double-blind, placebo-controlled, randomized study, all patients first received open-label simufilam 100 mg for 12 months. Patients were then randomized to receive either simufilam 100 mg or placebo for 6 months. 

About Cassava Sciences

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established. For more information, please visit: https://www.CassavaSciences.com